摘要
目的观察吉西他滨联合卡铂(GC方案)与吉西他滨联合顺铂(GP方案)治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及对生活质量的影响。方法将98例晚期NSCLC患者随机分为两组。GC组采用吉西他滨1 000 mg/m2,静脉滴注30 min,第1,8天,卡铂300 mg/m2,第1天;GP组采用顺铂30 mg/m2,第1～3天,吉西他滨用法同上。每3周为1个疗程。治疗2个疗程后进行疗效评价。采用EORTC QLQ-C30和QLQ-LC13问卷对治疗前、后症状和生活质量的改变进行评价。结果总有效率、中位生存期、临床缓解时间、1年生存率两组对比差异无统计学意义(P均>0.05);两组主要毒副反应为骨髓抑制和恶心呕吐,其中GC组反应较轻;两组生存质量各领域包括功能子领域及症状子领域评分治疗后明显改善,GC组改善更明显。结论两套化疗方案治疗晚期NSCLC疗效确切。其中,GC方案耐受性较好,在改善生活质量方面有一定的优势。
Objective To observe the clinical effect of Gemcitabin plus carboplatin （GC） versus C, emcitabin plus cisplatin （GP） on advanced non-small cell lung cancer（NSCLC） and the influences on the quality of life （QOL）of the patients. Methods 98 cases of advanced NSCLC were randomly divided into two groups. The GC group received 1 000 mg/m^2 Gemcitabin intravenous drip in half an hour at day 1 and 8 ,and 300 mg/m^2 carboplatin at day 1. The GP group underwent the therapy of 30 mg/m^2 cisplatin from day 1 to 3, Gemcitabin the same to GC group. Each cycle was 3 weeks, and the clinical efficacy was evaluated after two cycles. The impact of treatment on disease-related symptoms and QOL were evaluated by EORTC QLQ-C 30 and QLQ-LC 13. Results There were no significantly difference between two groups including total effective rate, one year survival rate, median survival and disease median response time（ all P 〉 0.05 ）. The main side effects were myelosuppression and gastrointestinal reaction. And there was significant difference in these side effects between two groups. QOL in two groups were improved after treatment with the improvement of scores in all domains, including functional and symptom sub-domain, and the GC group was improved more significant than that of the GP group. Conclusion It is effective and safe for GC regimen and GP regimen to cure patients with advanced NSCLC ; GC regimen, with better overall tolerability, has certain advantages in improving the QOL and symptoms of advanced NSCLC patients.
出处
《中华全科医学》
2010年第1期58-59,共2页
Chinese Journal of General Practice
关键词
非小细胞肺癌
晚期
生活质量
Non-small cell lung cancer
Advanced
Quality of life
